Inovio prices $75M stock offering weeks after first FDA approval
What's the deal? Inovio PharmaceuticalsDealroom has a profile for this one. Try Dealroom →, a biotech developing DNA medicines for HPV-related diseases, cancer, and infectious diseases, has priced a $75 million public offering. The post-IPO equity raise comprises 58,747,235 shares at $1.05 each, plus pre-funded warrants, and is expected to close on or about November 9, 2026.
The players: Jefferies and Piper SandlerDealroom has a profile for this one. Try Dealroom → are joint book-running managers; H.C. Wainwright & Co.Dealroom has a profile for this one. Try Dealroom → is lead manager. The underwriters hold a 30-day option to buy up to 10,714,285 additional shares.
Why now? The timing follows a milestone: on October 30, the US Food and Drug Administration granted accelerated approval to VOCERYQ, formerly INO-3107, Inovio's first commercial product. The approval requires a confirmatory study, and the fresh capital could support both launch and follow-up work.
What could go wrong? This is Inovio's third equity offering of 2026. It raised about $17.5 million in April and $20 million in July, and in May said cash on hand was expected to fund operations only into the first quarter of 2027. Repeated raises underline heavy funding needs and dilution risk for existing shareholders.
The signal: At $75 million, this is a sizeable raise for Inovio — but it ranks in roughly the 28th percentile by amount against comparable deals, modest by broader market standards. For a newly commercial biotech, the offering buys runway to turn a first approval into revenue; whether it closes that gap depends on terms and how far the proceeds stretch.
Read more: pr.roundupweb.com
Image credit: WaStateGov
